Skip to main
RNXT

RenovoRx (RNXT) Stock Forecast & Price Target

RenovoRx (RNXT) Analyst Ratings

Based on 2 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

RenovoRx is well positioned for long term growth due to the strong commercialization of their FDA-cleared RenovoCath medical device and continued progress in their clinical trials. The company is expected to have significant revenue growth in 2026 and 2027, and its current valuation is attractive considering the potential market opportunities. Risks to the company include its balance sheet and liquidity risks, as well as uncertainties related to product development and regulatory approvals. However, the potential market for RenovoRx's therapies presents high rewards for investors.

Bears say

RenovoRx is facing significant challenges as it continues to develop its TAMP platform and drug candidate RenovoGem. Despite positive interim analysis results in 2023 and 2025, the overall market potential for pancreatic cancer treatment remains low, and the commercialization of RenovoCath may not be enough to support the company's financial growth in the near future. Investor confidence may also be affected by the limited success of previous TAMP therapies and the highly competitive landscape of the biopharmaceutical industry.

RenovoRx (RNXT) has been analyzed by 2 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of RenovoRx and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About RenovoRx (RNXT) Forecast

Analysts have given RenovoRx (RNXT) a Strong Buy based on their latest research and market trends.

According to 2 analysts, RenovoRx (RNXT) has a Strong Buy consensus rating as of Sep 16, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $8.75, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $8.75, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

RenovoRx (RNXT)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.